Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Looking into global blood therapeutics s return on capital employed | Mind Blowing Facts

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million. In Q3, Global Blood Therapeutics brought in $52.05 million in sales but lost $70.99 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.